Novartis Says Breakthrough Therapy LDK378 Shows Marked Clinical Response
June 03, 2013 at 11:32 AM EDT
Novartis (NYSE: NVS ) today announced data on its investigational compound LDK378 showing a marked clinical response in 78 patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who had progressed during or after crizotinib therapy or had not been previously treated with crizotinib[1]. The
